NASDAQ:REGN Archives - BioPharmaJournal

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi Announce Positive Pivotal...

Matt Wade - January 28, 2022 0

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Announces Q3 2020 Revenue Of $2.29 Boosted...

Kate Hudson - November 25, 2020 0

Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) COVID-19 Drug Cocktail Seeing Increase In Demand...

Gavins Felicity - October 20, 2020 0

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) To Be Evaluated In RECOVERY Phase 3...

Matt Wade - September 24, 2020 0

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Clinches $450 Million Deal From The US...

Gavins Felicity - July 15, 2020 0

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Commences Clinical Trials For REGN-COV2 As A...

Gavins Felicity - June 18, 2020 0

Intellia Therapeutics Inc. (NASDAQ:NTLA) And Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Expand Their...

Gavins Felicity - June 12, 2020 0

Chimerix Inc (NASDAQ: CMRX) Receives $25.3 Million Procurement Contract For TEMBEXA

Kate Hudson - July 4, 2022 0

Chimerix Inc (NASDAQ: CMRX) has received a $25.3 million contract agreement from the Public Health Agency of Canada for the procurement of TEMBEX (brincidofovir)....

Regulus Therapeutics Inc (NASDAQ: RGLS) Pleased after FDA Approved its Orphan...

July 1, 2022

Cannabis Stocks Deeply Oversold with Big Growth Ahead (TLRY, SGMD, OGI,...

June 30, 2022

Ocugen Inc (NASDAQ: OCGN) Announces the Successful Publication of Positive Outcomes...

June 30, 2022

Why Your Body Needs Nitric Oxide Boost Beets For More Energy...

June 28, 2022

Tag: NASDAQ:REGN

Recent Post